HTG Molecular Diagnostics Inc.
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DL… Read more
Market Cap & Net Worth: HTG Molecular Diagnostics Inc. (HTGMQ)
HTG Molecular Diagnostics Inc. (PINK:HTGMQ) has a market capitalization of $221.42 ($221.42) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #49619 globally and #15173 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HTG Molecular Diagnostics Inc.'s stock price $0.00 by its total outstanding shares 2214233 (2.21 Million).
HTG Molecular Diagnostics Inc. Market Cap History: 2015 to 2025
HTG Molecular Diagnostics Inc.'s market capitalization history from 2015 to 2025. Data shows change from $1.74 Billion to $221.42 (-81.75% CAGR).
HTG Molecular Diagnostics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HTG Molecular Diagnostics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.39x
HTG Molecular Diagnostics Inc.'s market cap is 1.39 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.74 Billion | $4.04 Million | -$21.40 Million | 429.96x | N/A |
| 2016 | $892.78 Million | $5.13 Million | -$26.04 Million | 173.94x | N/A |
| 2017 | $809.08 Million | $14.76 Million | -$18.96 Million | 54.82x | N/A |
| 2018 | $1.01 Billion | $21.50 Million | -$16.45 Million | 47.08x | N/A |
| 2019 | $279.79 Million | $19.20 Million | -$19.30 Million | 14.57x | N/A |
| 2020 | $127.27 Million | $8.55 Million | -$20.87 Million | 14.89x | N/A |
| 2021 | $144.01 Million | $8.91 Million | -$17.15 Million | 16.17x | N/A |
| 2022 | $8.83 Million | $6.37 Million | -$21.59 Million | 1.39x | N/A |
Competitor Companies of HTGMQ by Market Capitalization
Companies near HTG Molecular Diagnostics Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to HTG Molecular Diagnostics Inc. by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
HTG Molecular Diagnostics Inc. Historical Marketcap From 2015 to 2025
Between 2015 and today, HTG Molecular Diagnostics Inc.'s market cap moved from $1.74 Billion to $ 221.42, with a yearly change of -81.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $221.42 | -66.67% |
| 2024 | $664.27 | -70.00% |
| 2023 | $2.21K | -99.97% |
| 2022 | $8.83 Million | -93.87% |
| 2021 | $144.01 Million | +13.15% |
| 2020 | $127.27 Million | -54.51% |
| 2019 | $279.79 Million | -72.36% |
| 2018 | $1.01 Billion | +25.12% |
| 2017 | $809.08 Million | -9.38% |
| 2016 | $892.78 Million | -48.62% |
| 2015 | $1.74 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of HTG Molecular Diagnostics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $221.42 USD |
| MoneyControl | $221.42 USD |
| MarketWatch | $221.42 USD |
| marketcap.company | $221.42 USD |
| Reuters | $221.42 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.